TOP TEN perturbations for 39020_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39020_at
Selected probe(set): 210792_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39020_at (210792_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-2.5417395Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (late se MCP)
Relative Expression (log2-ratio):2.3629026Number of Samples:15 / 2
| Experimental | uterine/pelvic pathology study 2 (pro. MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | uterine/pelvic pathology study 2 (late se MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. |
oncolytic herpes simplex virus study 1 / mock infected peripheral nerve sheath tumor (90-8) cell sample
Relative Expression (log2-ratio):-2.0757084Number of Samples:2 / 2
| Experimental | oncolytic herpes simplex virus study 1 |
| Human malignant peripheral nerve sheath tumor (90-8) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (90-8) cell sample |
| Human malignant peripheral nerve sheath tumor (90-8) cells mock infected for 6 hours. |
tunicamycin study 2 (2ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):-1.9948559Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
glioma study 16 (LN-18) / normal astrocyte sample
Relative Expression (log2-ratio):1.9744406Number of Samples:2 / 3
| Experimental | glioma study 16 (LN-18) |
| Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2. | |
| Control | normal astrocyte sample |
| Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
PMA study 3 (shRNA cycT1) / cycT1 depletion study 1 (shRNA)
Relative Expression (log2-ratio):-1.9284172Number of Samples:2 / 2
| Experimental | PMA study 3 (shRNA cycT1) |
| Jurkat cells were transduced with shRNA against cyclin T1 and then treated with 10ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
| Control | cycT1 depletion study 1 (shRNA) |
| Jurkat cells were transduced with shRNA against cyclin T1 and then mock treated. |
tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):-1.9098969Number of Samples:3 / 3
| Experimental | tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 DICER1(-/-) cell sample |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
uterine/pelvic pathology study 2 (mid-se MCP) / uterine/pelvic pathology study 2 (late se MCP)
Relative Expression (log2-ratio):1.8486624Number of Samples:14 / 2
| Experimental | uterine/pelvic pathology study 2 (mid-se MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the mid-secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | uterine/pelvic pathology study 2 (late se MCP) |
| Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. |
colorectal adenoma study 2 / normal colon tissue
Relative Expression (log2-ratio):-1.8239174Number of Samples:5 / 6
| Experimental | colorectal adenoma study 2 |
| Laser microdissected human adenoma sample. | |
| Control | normal colon tissue |
| Laser microdissected human colonic epithelial cells sample. |
endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)
Relative Expression (log2-ratio):1.776475Number of Samples:12 / 20
| Experimental | endometriosis study 6 (minimal/mild endo.; pro. MCP) |
| Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded. | |
| Control | normal endometrium tissue (pro. MCP) |
| Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. |